NDA 021583 · Pfizer
Depo-Subq Provera 104
Medroxyprogesterone Acetate · Subcutaneous
Last checked: Nov 19, 2026Latest source record: Dec 12, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2004
Dec 17, 2004
Approved uses
3
Original approval plus efficacy supplements
Registered trials
183
47 Phase 3, 16 recruiting
FAERS reports
10,076
8,739 serious, 311 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: LOSS OF BONE MINERAL DENSITY • Women who use depo-subQ provera 104 may lose significant bone mineral density. Bone loss is greater with increasing duration of use and may not be completely reversible [see Warnings and Precautions (5.1) ] . • It is unknown if use of depo-subQ provera 104 during adolescence or early adulthood, a critical period of bone accretion, will reduce peak bone mass and increase the risk for osteoporotic fracture in later life [see Warnings and Precautions (5.1) ] . • Depo-subQ provera 104 is not recommended as a long-term (i.e., longer than 2 years) birth control method or medical therapy for endometriosis-associated pain unless other options are considered inadequate [see Indications and Usage (1) and Warnings and Precautions (5.1) ] . WARNING: LOSS OF BONE MINERAL DENSITY See full prescribing information for complete boxed warning . • Women who use...
What it is approved for
From the label in effect Dec 18, 2025.
Depo-subQ provera 104 is indicated in females of reproductive age for: • Prevention of pregnancy and • Management of endometriosis-associated pain. Depo-subQ provera 104 is a progestin that is indicated in females of reproductive age for: • Prevention of pregnancy. ( 1 ) • Management of endometriosis-associated pain. ( 1 ) Limitations of Use : Use of depo-subQ provera 104 is not recommended as a long-term (i.e., longer than 2 years) birth control method or medical therapy for endometriosis-associated pain unless other options are considered inadequate. ( 1 , 5.1 ) Limitations of Use : The use of depo-subQ provera 104 is not recommended as a long-term (i.e., longer than 2 years) birth control method or medical therapy for endometriosis-associated pain unless other options are considered inadequate [see Dosage and Administration (2.1) and Warnings and Precautions (5.1) ].
Mechanism: Depo-subQ provera 104 inhibits the secretion of gonadotropins, which primarily prevents follicular maturation and ovulation and causes thickening of cervical mucus. These actions contribute to its contraceptive effect. Suppression of serum estradiol concentrations is likely to be responsible for the therapeutic effect on endometriosis-associated pain.
Therapeutic areas: Endocrinology and women's health
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 4, 2020 Supplement 34 · Efficacy LetterLabel
- Dec 4, 2020 Supplement 33 · Efficacy LetterLabel
- Dec 17, 2004 Original approval · Type 3 - New Dosage Form ReviewLabelLetter
1 products under this application
- DEPO-SUBQ PROVERA 104 · MEDROXYPROGESTERONE ACETATE 104MG/0.65ML · INJECTABLE, SUBCUTANEOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Medroxyprogesterone" as an intervention, any sponsor and status, largest first.
- The Evidence for Contraceptive Options and HIV Outcomes TrialPivotal-lookingCompleted
FHI 360Academic, hospital or other
NCT02550067 · 7,830 participants · Start Dec 14, 2015 · Primary completion Oct 31, 2018
Drug: DMPA; LNG and 1 more · For: HIV; Contraception
Sites: Manzini, Eswatini; Kisumu, Kenya; Brits, South Africa · 12 sites in all
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH
NCT00006324 · 6,360 participants · Start Dec 1999
Drug: Ethinyl estradiol/levonorgestrel; Medroxyprogesterone acetate · For: HIV Infections
Sites: Research Triangle Park, North Carolina
- Heart and Estrogen-Progestin Replacement Study (HERS)Pivotal-lookingCompleted
University of California, San FranciscoAcademic, hospital or other
NCT00319566 · 2,430 participants · Start Jul 1992
Drug: Premarin .625 mg daily plus medroxyprogesterone 2.5 mg daily · For: Coronary Heart Disease
Sites: San Francisco, California
- Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal OsteoporosisPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT00808132 · 1,886 participants · Start Jan 2009 · Primary completion Feb 2011
Drug: bazedoxifene 20 mg/ conjugated estrogens 0.45 mg; bazedoxifene 20 mg/ conjugated estrogens 0.625 mg and 3 more · For: Menopause; Osteoporosis
Sites: Birmingham, Alabama; Mobile, Alabama; Chandler, Arizona · 178 sites in all
- Multi-centre Clinical Trial on Hormone Replacement Treatment in ChinaPivotal-lookingStatus unknown
Peking Union Medical College HospitalAcademic, hospital or other
NCT01698164 · 1,200 participants (planned) · Start Dec 2008 · Primary completion Oct 2012
Drug: estradiol plus MPA; Ximingting Tablet and 1 more · For: Menopausal Syndrome; Cardiovascular Disease; Osteoporosis and 1 more
Sites: Beijing, China
- Doxycycline and Progestin Therapy for Chronic Endometritis(CE) in Patients With Recurrent Reproductive Failure(RRF)Pivotal-lookingRecruiting
Fang WangAcademic, hospital or other
NCT07488949 · 1,000 participants (planned) · Start Apr 9, 2024 · Primary completion Dec 31, 2030
Drug: Doxycycline combined with Medroxyprogesterone; Doxycycline combined with placebo · For: Chronic Endometritis
Sites: Lanzhou, China
- Randomized Study of Oral Contraceptives or Hormone Replacement Therapy in Women With Systemic Lupus ErythematosusPivotal-lookingCompleted
National Center for Research Resources (NCRR)NIH
NCT00006133 · 970 participants · Start Jun 2000
Drug: estradiol; ethinyl estradiol and 2 more · For: Systemic Lupus Erythematosus
Sites: Birmingham, Alabama; Los Angeles, California; San Francisco, California · 17 sites in all
- Long-Acting Reversible ContraceptionPivotal-lookingCompleted
FHI 360Academic, hospital or other
NCT01299116 · 916 participants · Start Dec 2011 · Primary completion Jun 2016
Drug: DMPA; oral contraceptives and 3 more · For: Contraception
Sites: Chapel Hill, North Carolina
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- breast cancer female2,993
- breast cancer1,819
- meningioma844
- breast cancer metastatic434
- drug ineffective309
- off label use235
- oestrogen receptor assay positive215
- pain200
- ovarian cancer186
- nausea183
- progesterone receptor assay positive178
- fatigue167
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1,186 |
| 2005 | 855 |
| 2006 | 782 |
| 2007 | 197 |
| 2008 | 300 |
| 2009 | 481 |
| 2010 | 1,841 |
| 2011 | 504 |
| 2012 | 280 |
| 2013 | 89 |
| 2014 | 72 |
| 2015 | 123 |
| 2016 | 122 |
| 2017 | 113 |
| 2018 | 153 |
| 2019 | 217 |
| 2020 | 272 |
| 2021 | 212 |
| 2022 | 200 |
| 2023 | 240 |
| 2024 | 347 |
| 2025 | 791 |
| 2026 | 699 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Depo-Subq Provera 104 (Medroxyprogesterone Acetate)
2024 spending
$53K
Beneficiaries
344
927 claims
Per beneficiary
$154
$83.05 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $103,121 |
| 2021 | $35,629 |
| 2022 | $28,222 |
| 2023 | $31,665 |
| 2024 | $52,877 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Different regimens of menopausal hormone therapy for improving sleep quality: a systematic review and meta-analysis.
Pan Z, Wen S, Qiao X, et al. · Menopause 2022 · Meta-Analysis, Systematic Review
- Systemic hormonal contraception initiation after abortion: A systematic review and meta-analysis.
Kim C, Nguyen AT, Berry-Bibee E, et al. · Contraception 2021 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Efficacy and safety of pharmacological cachexia interventions: systematic review and network meta-analysis.
Saeteaw M, Sanguanboonyaphong P, Yoodee J, et al. · BMJ Support Palliat Care 2021 · Systematic Review, Network Meta-Analysis
- Atypical polypoid adenomyoma follow-up and management: Systematic review of case reports and series and meta-analysis.
Biasioli A, Londero AP, Orsaria M, et al. · Medicine (Baltimore) 2020 · Meta-Analysis, Systematic Review
- The effect of progestin therapy in advanced and recurrent endometrial cancer: A systematic review and meta-analysis.
van Weelden WJ, Birkendahl PB, Lalisang RI, et al. · BJOG 2023 · Meta-Analysis, Systematic Review
- A randomized controlled trial of medroxyprogesterone acetate and psychotherapy for the treatment of pelvic congestion.
Farquhar CM, Rogers V, Franks S, et al. · Br J Obstet Gynaecol 1989 · Clinical Trial, Randomized Controlled Trial
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.